Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient

Pharmaceuticals

Anita Abhyankar¹  Elliot Tapper² 

[1] Department of Medicine, St. Elizabeth’s Medical Center, Tufts University School of Medicine, 736 Cambridge Street, Brighton, MA 02135, USA; E-Mail:;Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street Suite 8E, Boston, MA 02115, USA; E-Mail:

关键词: autoimmune liver disease;    autoimmune hepatitis;    primary biliary cirrhosis;    primary sclerosing cholangitis;    overlap syndrome;   

DOI  :  10.3390/ph7010018

来源: mdpi

【 摘 要 】

Autoimmune liver disease management goals are primarily slowing disease progression and symptomatic treatment. There are few options for curative medical management other than transplant for a spectrum of autoimmune liver disease that encompasses autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis as well as their overlap syndromes. These diseases are managed primarily with immunosuppressive therapy. Herein, we review the current literature, detailing the promise and pitfalls of the recommended immunosuppressive therapy for these challenging diseases.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.